ALK-Abello rises on positive Phase 2 peanut allergy trial data

Alk-Abello A/S

20/04/2026 14:20

** Shares in Danish allergy solutions maker ALK-Abello ALKb.CO rise over 8% after it reported positive phase 2 results from its ALLIANCE trial

** Treatment with the peanut tablet was safe and well-tolerated, the company says, adding that in the phase 2 trial, 49% of patients on the highest dose tolerated 300 mg of peanut protein, compared with 18% on placebo

** At the same dose, 31% tolerated 600 mg versus 8% with placebo, while 22% tolerated 1,000 mg compared with 2% in the placebo group

** Phase 3 development expected to begin late 2026, the company says

** If gains hold, ALK-Abello shares are on track for their best day since November 2025

 (Reporting by Elviira Luoma)

 ((Elviira.luoma@thomsonreuters.com))